Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash & Equivalents (2019 - 2025)

Historic Cash & Equivalents for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $278.9 million.

  • Legend Biotech's Cash & Equivalents fell 3927.56% to $278.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $278.9 million, marking a year-over-year decrease of 3927.56%. This contributed to the annual value of $1.3 billion for FY2024, which is 0.0% changed from last year.
  • As of Q3 2025, Legend Biotech's Cash & Equivalents stood at $278.9 million, which was down 3927.56% from $266.6 million recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Cash & Equivalents peaked at $1.3 billion during Q4 2023, and registered a low of $201.3 million during Q2 2024.
  • Its 5-year average for Cash & Equivalents is $609.1 million, with a median of $459.3 million in 2024.
  • As far as peak fluctuations go, Legend Biotech's Cash & Equivalents soared by 44662.56% in 2021, and later tumbled by 8368.06% in 2024.
  • Over the past 5 years, Legend Biotech's Cash & Equivalents (Quarter) stood at $688.9 million in 2021, then grew by 14.09% to $786.0 million in 2022, then soared by 62.55% to $1.3 billion in 2023, then plummeted by 77.56% to $286.7 million in 2024, then fell by 2.74% to $278.9 million in 2025.
  • Its Cash & Equivalents was $278.9 million in Q3 2025, compared to $266.6 million in Q2 2025 and $441.7 million in Q1 2025.